| 前收市價 | 3.6000 |
| 開市 | 3.6000 |
| 買盤 | 5.4000 |
| 賣出價 | 7.1000 |
| 拍板 | 45.00 |
| 到期日 | 2026-01-16 |
| 今日波幅 | 3.6000 - 3.6000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 73 |
Insider MonkeyThe City With the highest HIV/AIDS Rates in the US
We recently compiled a list of 20 Cities With the Highest HIV/AIDS Rates in the US and in this article, we will talk about the city with the highest HIV/AIDS rates in the US. HIV Incidence and Prevalence in the United States The government of the United States has set a goal to reduce the […]
InvestorPlaceThe 3 Most Undervalued Pharma Stocks to Buy in June 2024
Pharma stocks have two unique characteristics that can make them great investments for many individuals. First, unlike the vast majority of equities, undervalued pharma stocks can rally even when the economy is performing miserably. And secondly, a few data points can rather quickly transform a pharma company that’s been a loser for many years on end into a huge winner. Consider, for example, the case of Viking Therapeutics (NASDAQ: VKTX) whose shares changed hands in the single digits for many
BenzingaGSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
On Sunday, GSK plc (NYSE:GSK) released results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex for relapsed or refractory multiple myeloma. The data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. On the primary endpoint of progression-free survival (PFS), the belantamab mafodotin comb
